Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group

作者：Kentepozidis N^*; Kotsakis A; Soultati A; Agelaki S; Christophylakis Ch; Agelidou M; Chelis L; Papakotoulas P; Vamvakas L; Zafiriou Z; Samonis G; Georgoulias V

来源：Cancer Chemotherapy and Pharmacology, 2013, 71(3): 605-612.

DOI：10.1007/s00280-012-2037-1

• Non-small-cell lung cancer
• Docetaxel
• Cisplatin
• Bevacizumab
• Angiogenesis and endothelium

The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic non-small-cell lung cancer (NSCLC), and bevacizumab (B) improves the efficacy of frontline chemotherapy. This phase II study was designed in order to explore the efficacy and safety of DCB regiment in this setting.
Chemotherapy-na < ve patients (n = 48) with measurable, histologically confirmed non-squamous, IIIB (wet)/IV NSCLC, and PS 0-2 were eligible. Patients received D (75 mg/m(2) IV), C (80 mg/m(2) IV), and B (15 mg/kg IV) every 3 weeks. Maintenance of bevacizumab was not mandatory.
Complete and partial responses were achieved in two (4.2 %) and 14 (29.2 %) patients, respectively [overall response rate: 33.3 %; 95 % CI = 20.0-46.7 %], whereas stable disease was documented in 14 [disease control rate = 62.5 %; 95 % CI = 48.8-76.2 %]. The median progression-free survival was 4.4 months and the median overall survival 13.3 months. Treatment-related grade 3 or 4 hematologic adverse events were leukopenia, neutropenia, and anemia in 8.4, 18.7, and 2.1 % of the patients, respectively. Febrile neutropenia occurred in three (6.3 %) patients. Bleeding was documented in 4 % of the patients, thrombotic episodes in 8 %, and proteinuria in 3 %. There was one treatment-related death.
Frontline DCB in patients with advanced non-squamous NSCLC is an active regimen with manageable toxicity and merits to be further investigated.

• 出版日期2013-3